Dr. DeFilipp explores innovative strategies for managing chronic graft-versus-host disease, emphasizing personalized treatment and the shift towards targeted therapies.
Optimizing Treatment Sequencing in Chronic Graft Versus Host Disease After Allogeneic Transplant
Explore the complexities of assessing chronic graft-versus-host disease severity and the role of NIH criteria in treatment decisions.
A patient with chronic graft-versus-host disease faces treatment challenges, highlighting the need for effective management strategies post-transplant.
Explore effective management strategies for chronic graft-versus-host disease, focusing on transitioning from steroids to second-line therapies like ruxolitinib.
Explore effective third-line treatments for chronic GVHD, focusing on the latest FDA-approved therapies and their impact on patient outcomes.
Explore the complexities of interpreting clinical trial results versus real-world experiences in chronic GVHD treatment options.
Explore innovative combination strategies for chronic GVHD treatment, focusing on emerging therapies and their potential to enhance patient outcomes.
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
4
Multiomic Real-World Data Predict Outcomes in Metastatic Breast Cancer
5